Emergent BioSolutions raises 2025 guidance to $835M revenue and $210M EBITDA as international MCM sales surge (NYSE:EBS)
Emergent BioSolutionsEmergent BioSolutions(US:EBS) Seeking Alpha·2025-10-30 00:57

Group 1 - The article does not provide any specific content related to a company or industry [1]